Total Payments
$7,243
2023 Payments
$19.10
Companies
28
Transactions
347
Medicare Patients
1,150
Medicare Billing
$122,382
Payment Breakdown by Category
Food & Beverage$7,243 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,243 | 347 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,008 | 46 | $0 (2022) |
| Amgen Inc. | $972.03 | 43 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $819.64 | 70 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $755.79 | 36 | $0 (2020) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $650.75 | 33 | $0 (2022) |
| PFIZER INC. | $471.22 | 9 | $0 (2023) |
| Astellas Pharma US Inc | $463.05 | 6 | $0 (2020) |
| GE HealthCare | $426.38 | 3 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $305.87 | 21 | $0 (2019) |
| Arbor Pharmaceuticals, Inc. | $265.59 | 16 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $19.10 | 1 | PFIZER INC. ($19.10) |
| 2022 | $539.83 | 20 | Amgen Inc. ($153.58) |
| 2021 | $886.38 | 38 | GE HEALTHCARE ($301.85) |
| 2020 | $851.80 | 47 | Janssen Pharmaceuticals, Inc ($229.15) |
| 2019 | $1,763 | 74 | Amgen Inc. ($381.12) |
| 2018 | $1,654 | 80 | Novartis Pharmaceuticals Corporation ($353.27) |
| 2017 | $1,529 | 87 | Boehringer Ingelheim Pharmaceuticals, Inc. ($226.50) |
All Payment Transactions
347 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/12/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/22/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.83 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: DIABETES | ||||||
| 09/07/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/24/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: DIABETES | ||||||
| 08/22/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Cardiology | ||||||
| 07/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: DIABETES | ||||||
| 06/27/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $104.16 | General |
| Category: Cardiology | ||||||
| 06/23/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Cardiology | ||||||
| 06/09/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/01/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/05/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $124.53 | General |
| 04/20/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: DIABETES | ||||||
| 04/07/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $10.67 | General |
| Category: Cardiology | ||||||
| 03/23/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 03/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: DIABETES | ||||||
| 02/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: DIABETES | ||||||
| 02/11/2022 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $9.34 | General |
| Category: Heart Failure and Hypertension | ||||||
| 01/24/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: DIABETES | ||||||
| 01/18/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.85 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/28/2021 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.73 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/08/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: DIABETES | ||||||
| 12/07/2021 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $14.50 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/11/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 252 | 252 | $37,454 | $8,506 |
| 2022 | 7 | 239 | 347 | $88,457 | $28,207 |
| 2021 | 8 | 294 | 472 | $120,770 | $43,151 |
| 2020 | 10 | 365 | 520 | $130,280 | $42,518 |
Total Patients
1,150
Total Services
1,591
Medicare Billing
$122,382
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 107 | 107 | $27,713 | $5,955 | 21.5% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 37 | 37 | $4,773 | $1,448 | 30.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 108 | 108 | $4,968 | $1,103 | 22.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 31 | 31 | $41,349 | $11,452 | 27.7% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 30 | 60 | $11,230 | $5,307 | 47.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 26 | 104 | $11,128 | $5,061 | 45.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 58 | 58 | $13,294 | $3,509 | 26.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 35 | 35 | $7,915 | $1,793 | 22.7% |
| 78803 | Nuclear medicine study, 1 area with spect | Facility | 2022 | 16 | 16 | $2,064 | $648.99 | 31.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 27 | 27 | $1,237 | $310.26 | 25.1% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2022 | 16 | 16 | $240.00 | $125.48 | 52.3% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 49 | 49 | $62,671 | $19,320 | 30.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2021 | 50 | 96 | $14,880 | $8,941 | 60.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 44 | 176 | $18,832 | $8,305 | 44.1% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2021 | 47 | 47 | $9,635 | $2,964 | 30.8% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 52 | 52 | $11,596 | $2,670 | 23.0% |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | Facility | 2021 | 13 | 13 | $1,677 | $481.66 | 28.7% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2021 | 12 | 12 | $684.00 | $213.60 | 31.2% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 13 | 13 | $585.00 | $154.31 | 26.4% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2021 | 14 | 14 | $210.00 | $102.04 | 48.6% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2020 | 43 | 43 | $54,997 | $16,594 | 30.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2020 | 44 | 84 | $13,020 | $7,198 | 55.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2020 | 38 | 152 | $16,264 | $6,997 | 43.0% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2020 | 65 | 65 | $13,325 | $4,144 | 31.1% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2020 | 51 | 52 | $11,596 | $2,638 | 22.7% |
About Dr. Anne Bullock, M.D
Dr. Anne Bullock, M.D is a Nuclear Cardiology healthcare provider based in Griffin, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1477547784.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anne Bullock, M.D has received a total of $7,243 in payments from pharmaceutical and medical device companies, with $19.10 received in 2023. These payments were reported across 347 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($7,243).
As a Medicare-enrolled provider, Bullock has provided services to 1,150 Medicare beneficiaries, totaling 1,591 services with total Medicare billing of $122,382. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Cardiology
- Location Griffin, GA
- Active Since 09/01/2005
- Last Updated 10/31/2022
- Taxonomy Code 207UN0901X
- Entity Type Individual
- NPI Number 1477547784
Products in Payments
- XARELTO (Drug) $806.88
- Repatha (Biological) $767.72
- ENTRESTO (Drug) $755.79
- LifeVest (Device) $650.75
- JARDIANCE (Drug) $515.99
- PRADAXA (Drug) $476.56
- VYNDAQEL (Drug) $444.48
- PRALUENT ALIROCUMAB INJECTION (Biological) $222.27
- Corlanor (Drug) $204.31
- NORTHERA (Drug) $155.65
- BRILINTA (Drug) $144.38
- Livalo (Drug) $133.74
- Bidil (Drug) $115.17
- Lexiscan (Drug) $98.69
- BEVYXXA (Drug) $94.07
- Edarbi (Drug) $84.31
- PRALUENT (Biological) $83.60
- ELIQUIS (Drug) $65.27
- MULTAQ (Drug) $55.75
- Surgical Care - CoSeal (Biological) $46.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.